Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2541-2546

  Casapao, Anthony M ^a   Davis, Susan L ^a,b   Barr, Viktorija O ^c   Klinker, Kenneth P ^d   Goff, Debra A ^e,f   Barber, Katie E ^a   Kaye, Keith S ^g,h   Mynatt, Ryan P ^h   Molloy, Leah M ^h   Pogue, Jason M ^h   Rybaka, Michael J ^a,h  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c ALEXIAN BROTHERS MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DETROIT MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; DAPTOMYCIN; LINEZOLID; METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ADULT; AGED; ANEMIA; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; BONE AND JOINT INFECTIONS; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NAUSEA; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; COMMUNITY-ACQUIRED INFECTIONS; MIDDLE AGED; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL;

AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; SKIN DISEASES, BACTERIAL;

EID: 84898634071     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02371-13     Document Type: Article

References (38)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. http://dx.doi.org/10.1086/595011.
2. van Hal SJ, Paterson DL. 2011. Systematic review and meta-Analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:405-410. http://dx.doi.org/10.1128/ AAC.01133-10.
3. Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S. 2011. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 66:1594-1599. http://dx.doi.org/10.1093/jac/dkr169.
4. Kelley PG, Gao W, Ward PB, Howden BP. 2011. Daptomycin nonsusceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J. Antimicrob. Chemother. 66:1057-1060. http://dx.doi.org/10.1093/jac/dkr066.
5. Joson J, Grover C, Downer C, Pujar T, Heidari A. 2011. Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure. J. Antimicrob. Chemother. 66:2186-2188. http://dx.doi.org/ 10.1093/jac/dkr234.
6. Ruiz ME, Guerrero IC, Tuazon CU. 2002. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin. Infect. Dis. 35:1018-1020. http://dx.doi.org/10.1086/342698.
7. Infectious Diseases Society of America. 2010. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50:1081-1083. http://dx.doi.org/10.1086/652237.
8. Forest Laboratories, Inc. July 2013. Telfaro (ceftaroline fosamil). Package information. Forest Laboratories, Inc., St. Louis, MO.
9. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T, CANVAS 1 investigators. 2010. CANVAS 1: the first phase III, randomized, double-blind studyevaluating ceftaroline fosamil for thetreatmentof patientswithcomplicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4):iv41-51. http://dx.doi.org/10.1093/jac/dkq254.
10. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T, CANVAS 2 investigators. 2010. CANVAS 2: the second phase III, randomized, doubleblind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4):iv53-iv65. http://dx.doi.org/10.1093/jac/dkq255.
11. File TM, Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA, FOCUS 1 investigators. 2011. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in communityacquired pneumonia. J. Antimicrob. Chemother. 66(Suppl 3):iii19-32. http://dx.doi.org/10.1093/jac/ dkr096.
12. Low DE, File TM, Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA, FOCUS 2 investigators. 2011. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-Acquired pneumonia. J. Antimicrob. Chemother. 66(Suppl 3):iii33-44. http://dx.doi.org/10. 1093/jac/dkr097.
13. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS, II. 2012. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J. Antimicrob. Chemother. 67: 1267-1270. http://dx.doi.org/10.1093/jac/dks006.
14. Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. 2013. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J. Infect. Chemother. 19:42-49. http://dx.doi.org/10.1007/s10156-012-0449-9.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829. http://dx.doi.org/10.1097/00003246-198510000-00009.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383. http://dx.doi.org/10.1016/0021-9681(87) 90171-8.
17. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Jr, Ryan T, Bashore T, Corey GR. 2000. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin. Infect. Dis. 30:633-638. http://dx.doi.org/10. 1086/313753.
18. Lew DP, Waldvogel FA. 2004. Osteomyelitis. Lancet 364:369-379. http://dx.doi.org/10.1016/S0140-6736(04)16727-5.
19. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak JM, Talan DA, Chambers HF, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55. http://dx.doi.org/10.1093/cid/ciq146.
20. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444. http://dx.doi.org/10.1128/JCM.39.7.2439-2444.2001.
21. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403. http://dx.doi.org/10.1093/jac/47.4.399.
22. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing, 23rd informational supplement. CLSI document M100-S23. CLSI, Wayne, PA.
23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42:377-381. http://dx.doi.org/10.1016/j.jbi.2008.08.010.
24. Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. 2013. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection. Antimicrob. Agents Chemother. 57: 4252-4259. http://dx.doi.org/10.1128/AAC. 00380-13.
25. Kopp BJ, Nix DE, Armstrong EP. 2004. Clinical and economic analysis of methicillin-susceptible and-resistant Staphylococcus aureus infections. Ann. Pharmacother. 38:1377-1382. http://dx.doi.org/10.1345/aph.1E028.
26. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-Analysis. Clin. Infect. Dis. 54: 755-771. http://dx.doi.org/10.1093/cid/cir935.
27. van Hal SJ, Paterson DL, Lodise TP. 2013. Systematic review and metaanalysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob. Agents Chemother. 57:734-744. http://dx.doi.org/10.1128/AAC.01568- 12.
28. Davis SL, Scheetz MH, Bosso JA, Goff DA, Rybak MJ. 29 July 2013. Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals. Pharmacotherapy 33:1256-1263. http://dx.doi.org/10.1002/phar.1327.
29. Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, Shukla SK. 2012. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob. Agents Chemother. 56:5296-5302. http://dx.doi.org/10.1128/AAC.00797-12.
30. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. 2013. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycinintermediate Staphylococcus aureus in a pharmacokinetic/ pharmacodynamic model. Antimicrob. Agents Chemother. 57:66-73. http://dx.doi.org/10.1128/AAC.01586-12.
31. Vidaillac C, Leonard SN, Rybak MJ. 2009. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycinintermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53:4712-4717. http://dx.doi.org/10.1128/AAC.00636-09.
32. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2010. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob. Agents Chemother. 54:1627-1632. http://dx.doi.org/10.1128/AAC.01788-09.
33. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ. 2013. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration-1 mg/L: a matched cohort study. Clin. Infect. Dis. 56: 1562-1569. http://dx.doi.org/10.1093/cid/cit112.
34. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. 2012. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin. Infect. Dis. 54:51-58. http://dx.doi.org/10.1093/cid/cir764.
35. Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665. http://dx.doi.org/10.1056/ NEJMoa053783.
36. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, Coombs GW, Johnson PD, Howden BP. 2011. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis. 204:340-347. http://dx.doi.org/10.1093/infdis/ jir270.
37. Zahar JR, Clec'h C, Tafflet M, Garrouste-Orgeas M, Jamali S, Mourvillier B, De Lassence A, Descorps-Declere A, Adrie C, Costa de Beauregard MA, Azoulay E, Schwebel C, Timsit JF. 2005. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-Associated pneumonia? Clin. Infect. Dis. 41:1224-1231. http://dx.doi.org/10.1086/496923.
38. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E, Infectious Diseases Society of America. 2012. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 54:e132-e173. http://dx.doi.org/10.1093/cid/ cis346.